|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
G04BD12
|
|
gptkbp:brand
|
gptkb:Myrbetriq
|
|
gptkbp:CASNumber
|
223673-61-8
|
|
gptkbp:chemicalFormula
|
beta-3 adrenergic agonist structure
|
|
gptkbp:contraindication
|
severe uncontrolled hypertension
|
|
gptkbp:developer
|
gptkb:Astellas_Pharma
|
|
gptkbp:drugInteraction
|
gptkb:digoxin
CYP2D6 substrates
|
|
gptkbp:eliminationHalfLife
|
50 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C21H24N4O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
mirabegron
|
|
gptkbp:IUPACName
|
(R)-2-(2-aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
beta-3 adrenergic receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:proteinBinding
|
71%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
hypertension
urinary tract infection
nasopharyngitis
|
|
gptkbp:synonym
|
gptkb:YM-178
|
|
gptkbp:usedFor
|
overactive bladder
|
|
gptkbp:bfsParent
|
gptkb:G04BE03
|
|
gptkbp:bfsLayer
|
6
|